NanoString Takes Option to Liver Cancer Gene Signature for Possible Assay Development | GenomeWeb

NEW YORK (GenomeWeb News) – NanoString Technologies today announced it has secured the option to exclusively license a 186-gene signature from the Broad Institute that may be useful in determining the prognosis of patients diagnosed with hepatocellular carcinoma, or HCC.

In addition to potentially being useful for HCC, the gene signature may also help determine the prognosis of patients with hepatitis C-related early stage cirrhosis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.